Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trofinetide - ACADIA Pharmaceuticals/Neuren Pharmaceuticals

Next Previous
Drug Profile

Trofinetide - ACADIA Pharmaceuticals/Neuren Pharmaceuticals

Alternative Names: DAYBUE; G-2Me-PE; Glycyl-2-methyl-L-prolyl-L-glutamic acid; Glycyl-L-2-methylprolyl-L-glutamic acid; NNZ-2566

Latest Information Update: 01 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neuren Pharmaceuticals
  • Developer ACADIA Pharmaceuticals; Neuren Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Anti-inflammatories; Glutamates; Neuropeptides; Neuroprotectants; Oligopeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Astrocyte inhibitors; Cytokine inhibitors; Glial cell inhibitors; Insulin-like growth factor I inhibitors; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rett syndrome; Fragile X syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Rett syndrome
  • Phase II Brain injuries; Fragile X syndrome; Traumatic brain injuries
  • Discontinued Autistic disorder; Multiple sclerosis

Most Recent Events

  • 25 Jun 2025 Acadia Pharmaceuticals plans to initiates a phase III trial for Rett syndrome in Japan in quarter three of 2025
  • 26 Feb 2025 ACADIA Pharmaceuticals anticipates the launch of Trofinetide in European Union in 2026
  • 14 Jan 2025 Preregistration for Rett syndrome (In adults, In children, In adolescents) in European Union (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top